

Debomoy K Lahiri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3192290/debomoy-k-lahiri-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255
papers

15,140
citations

70
h-index

114
g-index

308
ext. papers

16,545
ext. citations

5.6
avg, IF

6.63
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 255 | Human microRNA (miR-20b-5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers.. <i>Molecular Psychiatry</i> , 2022 , | 15.1 | 2 |
| 254 | Effects of microRNA-298 on APP and BACE1 translation differ according to cell type and 3'-UTR variation.. <i>Scientific Reports</i> , 2022 , 12, 3074 | 4.9 | 2 |
| 253 | Crossing the "Birth Border" for Epigenetic Effects.. <i>Biological Psychiatry</i> , 2022 , | 7.9 | 2 |
| 252 | How autism and Alzheimer's disease are TrAPPed. <i>Molecular Psychiatry</i> , 2021 , 26, 26-29 | 15.1 | 5 |
| 251 | Repeated electromagnetic field stimulation lowers amyloid- β peptide levels in primary human mixed brain tissue cultures. <i>Scientific Reports</i> , 2021 , 11, 621 | 4.9 | 3 |
| 250 | Regulation of the deleterious effects of binge-like exposure to alcohol during adolescence by α 7 nicotinic acetylcholine receptor agents: prevention by pretreatment with a α 7 negative allosteric modulator and emulation by a α 7 agonist in alcohol-preferring (P) male and female rats. <i>Psychopharmacology</i> , 2020 , 237, 2601-2611 | 4.7 | 3 |
| 249 | FMRP Regulates the Nuclear Export of Adam9 and Psen1 mRNAs: Secondary Analysis of an N-Methyladenosine Dataset. <i>Scientific Reports</i> , 2020 , 10, 10781 | 4.9 | 6 |
| 248 | Rivastigmine modifies the β secretase pathway and potentially early Alzheimer's disease. <i>Translational Psychiatry</i> , 2020 , 10, 47 | 8.6 | 25 |
| 247 | MicroRNA-298 reduces levels of human amyloid- β precursor protein (APP), β site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. <i>Molecular Psychiatry</i> , 2020 , | 15.1 | 33 |
| 246 | Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs. <i>Molecular Psychiatry</i> , 2020 , 25, 1651-1672 | 15.1 | 19 |
| 245 | M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from <i>Withania somnifera</i> . <i>Scientific Reports</i> , 2019 , 9, 13990 | 4.9 | 17 |
| 244 | APPealing for a role in cellular iron efflux. <i>Journal of Biological Chemistry</i> , 2019 , 294, 9365 | 5.4 | 4 |
| 243 | Novel Contribution of Secreted Amyloid- β Precursor Protein to White Matter Brain Enlargement in Autism Spectrum Disorder. <i>Frontiers in Psychiatry</i> , 2019 , 10, 165 | 5 | 21 |
| 242 | Biological Hallmarks of Cancer in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019 , 56, 7173-7187 | 6.2 | 20 |
| 241 | Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid- β Pathology in Female Rhesus Macaques (<i>Macaca Mulatta</i>). <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 115-126 | 4.3 | 6 |
| 240 | Moon missions spark the human imagination. <i>Science</i> , 2019 , 366, 581 | 33.3 | 4 |
| 239 | Lithium alters expression of RNAs in a type-specific manner in differentiated human neuroblastoma neuronal cultures, including specific genes involved in Alzheimer's disease. <i>Scientific Reports</i> , 2019 , 9, 18261 | 4.9 | 9 |

| | | |
|-----|---|--------|
| 238 | Novel upregulation of amyloid- β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5'-untranslated region: Implications in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2019 , 24, 345-363 ^{15.1} | 68 |
| 237 | Glucocorticoid Induced Leucine Zipper in Lipopolysaccharide Induced Neuroinflammation. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 432 | 5.3 4 |
| 236 | Latent consequences of early-life lead (Pb) exposure and the future: Addressing the Pb crisis. <i>NeuroToxicology</i> , 2018 , 68, 126-132 | 4.4 17 |
| 235 | (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018 , 15, 883-891 | 3 11 |
| 234 | P3-061: CONSTITUTIVE IN VIVO OVEREXPRESSION OF MIR146A AND MIR200B INDEPENDENTLY MODULATES LEVELS OF ALZHEIMER'S DISEASE (AD)- RELATED PROTEINS IN THE MOUSE HIPPOCAMPUS AND CEREBRAL CORTEX 2018 , 14, P1088-P1088 | |
| 233 | P2-269: ROLE OF THE REPRESSOR ELEMENT 1-SILENCING TRANSCRIPTION FACTOR (REST) IN NEURONAL DIFFERENTIATION AND ITS IMPLICATION IN ALZHEIMER'S DISEASE (AD) 2018 , 14, P780-P780 | |
| 232 | P3-050: GLUCOCORTICOID-INDUCED LEUCINE ZIPPER ANALOGS SUPPRESS NEUROINFLAMMATION IN ALZHEIMER'S DISEASE 2018 , 14, P1082-P1082 | |
| 231 | P3-053: (-)-PHENSERINE (PHEN) AND THE PREVENTION OF PRE-PROGRAMMED CELL DEATH IN ALZHEIMER'S DISEASE (AD) AND MILD TRAUMATIC BRAIN INJURY (MTBI) 2018 , 14, P1083-P1083 | |
| 230 | Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein and H-Ferritin. <i>Journal of Neurochemistry</i> , 2018 , 147, 831-848 | 6 44 |
| 229 | Nuclear factor-kappa B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 488-498 | 6 4 |
| 228 | A serine protease KLK8 emerges as a regulator of regulators in memory: Microtubule protein dependent neuronal morphology and PKA-CREB signaling. <i>Scientific Reports</i> , 2018 , 8, 9928 | 4.9 7 |
| 227 | A Tale of the Good and Bad: Remodeling of the Microtubule Network in the Brain by Cdk5. <i>Molecular Neurobiology</i> , 2017 , 54, 2255-2268 | 6.2 42 |
| 226 | [P21159]: DOES THE BIOCHEMICAL INVERSION OF ALZHEIMER'S DISEASE AND AUTISM SPECTRUM DISORDER PROVIDE LATE-LIFE PROTECTION FROM AN EARLY-LIFE CONDITION? 2017 , 13, P668-P669 | |
| 225 | [P3087]: MICRORNA AND GENE NETWORKS UNDERLYING THE INVERSE ASSOCIATION OF CANCER AND ALZHEIMER'S DISEASE 2017 , 13, P966-P966 | |
| 224 | When figures and data contradict text: MiR346 is apparently reduced in breast cancer tissue, contrary to claims by a paper's author. <i>Gene</i> , 2017 , 635, 46-47 | 3.8 |
| 223 | Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders. <i>Journal of Biological Chemistry</i> , 2017 , 292, 20353 ^{5.4} | 4 |
| 222 | Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism. <i>Journal of Psychiatric Research</i> , 2017 , 84, 153-160 | 5.2 4 |
| 221 | Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease. <i>Molecular Neurobiology</i> , 2017 , 54, 8063-8070 | 6.2 12 |

| | | | |
|-----|--|------|-----|
| 220 | [P4030]: ROLE OF SP1 AND OTHER TRANSCRIPTION FACTORS (TFS) IN ALZHEIMER'S DISEASE (AD) 2017 , 13, P1266-P1267 | | |
| 219 | [O40601]: SP1-MODULATING COMPOUNDS AS A NOVEL DRUG TARGET FOR ALZHEIMER'S DISEASE (AD) 2017 , 13, P1241-P1241 | | 1 |
| 218 | Potential for Stem Cells Therapy in Alzheimer's Disease: Do Neurotrophic Factors Play Critical Role?. <i>Current Alzheimer Research</i> , 2017 , 14, 208-220 | 3 | 39 |
| 217 | Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2017 , 14, 412-425 | 3 | 147 |
| 216 | A cardinal sin when researching neuropsin/KLK8: Thou shalt validate antibodies. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1068-1069 | 1.2 | 1 |
| 215 | Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. <i>Molecular Psychiatry</i> , 2016 , 21, 1333-41 | 15.1 | 28 |
| 214 | Finding novel distinctions between the sAPP β -mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue. <i>Scientific Reports</i> , 2016 , 6, 26052 | 4.9 | 25 |
| 213 | Transgenerational latent early-life associated regulation unites environment and genetics across generations. <i>Epigenomics</i> , 2016 , 8, 373-87 | 4.4 | 14 |
| 212 | Novel Nuclear Factor-KappaB Targeting Peptide Suppresses β Amyloid Induced Inflammatory and Apoptotic Responses in Neuronal Cells. <i>PLoS ONE</i> , 2016 , 11, e0160314 | 3.7 | 12 |
| 211 | Analysis of peripheral amyloid precursor protein in Angelman Syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2016 , 170, 2334-7 | 2.5 | 8 |
| 210 | P4-305: Novel Parallels and Distinctions Among App Metabolite Pathways in Alzheimer's Disease and Neurodevelopmental Disorders 2016 , 12, P1150-P1150 | | 1 |
| 209 | Epigenetics of dementia: understanding the disease as a transformation rather than a state. <i>Lancet Neurology, The</i> , 2016 , 15, 760-774 | 24.1 | 80 |
| 208 | What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry, the</i> , 2015 , 2, 756-764 | 23.3 | 11 |
| 207 | Daidzein Augments Cholesterol Homeostasis via ApoE to Promote Functional Recovery in Chronic Stroke. <i>Journal of Neuroscience</i> , 2015 , 35, 15113-26 | 6.6 | 35 |
| 206 | Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 815-43 | 4.3 | 58 |
| 205 | The neurobehavioral and molecular phenotype of Angelman Syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015 , 167A, 2623-8 | 2.5 | 20 |
| 204 | Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. <i>Current Alzheimer Research</i> , 2015 , 12, 32-46 | 3 | 192 |
| 203 | P4-156: Methionine restriction leads to A β reduction and neuroprotection: Implications in Alzheimer's disease pathogenesis and prevention 2015 , 11, P838-P839 | | 2 |

| | | | |
|-----|---|------|-----|
| 202 | P2-048: Does the mini-mental state examination (MMSE) measure a deeper biological process? modeling mmse score versus three selected mirna levels may reveal pathological roles in Alzheimer's disease progression 2015 , 11, P499-P500 | | |
| 201 | Significance of NF- κ B as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 471-87 | 6.4 | 99 |
| 200 | Variants in Ion Channel Genes Link Phenotypic Features of Bipolar Illness to Specific Neurobiological Process Domains. <i>Molecular Neuropsychiatry</i> , 2015 , 1, 23-35 | 4.9 | 5 |
| 199 | Cdk5 activity in the brain - multiple paths of regulation. <i>Journal of Cell Science</i> , 2014 , 127, 2391-400 | 5.3 | 121 |
| 198 | MicroRNA-339-5p down-regulates protein expression of β site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. <i>Journal of Biological Chemistry</i> , 2014 , 289, 5184-98 | 5.4 | 119 |
| 197 | Impact of acamprosate on plasma amyloid- β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. <i>Journal of Psychiatric Research</i> , 2014 , 59, 220-8 | 5.2 | 38 |
| 196 | Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. <i>Journal of Clinical Immunology</i> , 2014 , 34 Suppl 1, S80-5 | 5.7 | 13 |
| 195 | Role of early life exposure and environment on neurodegeneration: implications on brain disorders. <i>Translational Neurodegeneration</i> , 2014 , 3, 9 | 10.3 | 79 |
| 194 | Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 1-17 | 4.3 | 24 |
| 193 | Amyloid- β precursor protein synthesis inhibitors for Alzheimer's disease treatment. <i>Annals of Neurology</i> , 2014 , 76, 629-30 | 9.4 | 4 |
| 192 | P1-066: TREATMENT WITH SP1 INHIBITING DRUGS MODULATES APP AND BACE1 LEVELS IN HUMAN CELLS: IMPLICATION IN TESTING A NOVEL TARGET FOR ALZHEIMER'S DISEASE 2014 , 10, P327-P327 | | |
| 191 | P4-219: MICRORNA-339-5P IS DYSREGULATED IN ALZHEIMER'S DISEASE AND IS INVERSELY PROPORTIONAL TO BACE1 EXPRESSION: IMPLICATION IN TESTING NOVEL DRUG TARGETS 2014 , 10, P868-P868 | | |
| 190 | P3-407: NEUROPRESERVATIVE AND NEUROPROTECTIVE ROLE OF IVIG PREPARATION 2014 , 10, P779-P779 | | |
| 189 | Functional characterization of a competitive peptide antagonist of p65 in human macrophage-like cells suggests therapeutic potential for chronic inflammation. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 2409-21 | 4.4 | 8 |
| 188 | Human primary mixed brain cultures: preparation, differentiation, characterization and application to neuroscience research. <i>Molecular Brain</i> , 2014 , 7, 63 | 4.5 | 27 |
| 187 | Lessons from a BACE1 inhibitor trial: off-site but not off base. <i>Alzheimer's and Dementia</i> , 2014 , 10, S411-2.2 | | 54 |
| 186 | Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. <i>Alzheimer's and Dementia</i> , 2014 , 10, S62-75 | 1.2 | 58 |
| 185 | Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid- β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. <i>Current Alzheimer Research</i> , 2014 , 11, 608-22 | 3 | 37 |

| | | | |
|-----|--|------|-----|
| 184 | Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults. <i>Current Alzheimer Research</i> , 2014 , 11, 645-54 ³ | | 10 |
| 183 | Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. <i>Psychopharmacology</i> , 2013 , 228, 75-84 | 4.7 | 74 |
| 182 | PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid- β precursor protein via a tissue-specific proximal regulatory element (PRE). <i>BMC Genomics</i> , 2013 , 14, 68 | 4.5 | 6 |
| 181 | Autism as early neurodevelopmental disorder: evidence for an sAPP β -mediated anabolic pathway. <i>Frontiers in Cellular Neuroscience</i> , 2013 , 7, 94 | 6.1 | 45 |
| 180 | Editorial (Progress of <i>Current Alzheimer Research</i> and Future Direction). <i>Current Alzheimer Research</i> , 2013 , 10, 1-3 | 3 | 2 |
| 179 | Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e65978 | 3.7 | 35 |
| 178 | Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, β synuclein synthesis, interleukin-1 β release, and cholinergic action. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013 , 12, 117-28 | 2 | 19 |
| 177 | Gene \times environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS). <i>Epigenomics</i> , 2012 , 4, 685-99 | 4.4 | 7 |
| 176 | MicroRNA-153 physiologically inhibits expression of amyloid- β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. <i>Journal of Biological Chemistry</i> , 2012 , 287, 31298-310 | 5.4 | 122 |
| 175 | Prions: a piece of the puzzle?. <i>Science</i> , 2012 , 337, 1172 | 33.3 | 29 |
| 174 | Chromatographic separation of reaction products from the choline acetyltransferase and carnitine acetyltransferase assay: differential ChAT and CrAT activity in brain extracts from Alzheimer's disease versus controls. <i>Journal of Neurochemistry</i> , 2012 , 122, 672-80 | 6 | 7 |
| 173 | Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease. <i>Gene</i> , 2012 , 501, 63-78 | 3.8 | 7 |
| 172 | Tumor necrosis factor- β synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012 , 9, 106 | 10.1 | 140 |
| 171 | High-affinity choline uptake (HACU) and choline acetyltransferase (ChAT) activity in neuronal cultures for mechanistic and drug discovery studies. <i>Current Protocols in Neuroscience</i> , 2012 , Chapter 7, Unit 7.23 | 2.7 | 5 |
| 170 | Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. <i>Current Alzheimer Research</i> , 2012 , 9, 574-88 | 3 | 41 |
| 169 | The "LEARn" (latent early-life associated regulation) model: an epigenetic pathway linking metabolic and cognitive disorders. <i>Journal of Alzheimer's Disease</i> , 2012 , 30 Suppl 2, S15-30 | 4.3 | 13 |
| 168 | Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. <i>Experimental Neurology</i> , 2012 , 235, 402-18 | 5.7 | 31 |
| 167 | Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways. <i>Frontiers in Genetics</i> , 2012 , 3, 323 | 4.5 | 47 |

| | | | |
|-----|---|------|-----|
| 166 | Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. <i>Current Alzheimer Research</i> , 2012 , 9, 589-99 | 3 | 43 |
| 165 | N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. <i>Current Alzheimer Research</i> , 2012 , 9, 746-58 | 3 | 191 |
| 164 | Brain Aging: Influence of Early Life Events on Late-Life Brain Disorders 2012 , 67-78 | | |
| 163 | Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 23, 61-77 | 4.3 | 125 |
| 162 | The Alzheimer's amyloid β peptide (A β) binds a specific DNA A β interacting domain (AID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif. <i>Gene</i> , 2011 , 488, 1-12 | 3.8 | 83 |
| 161 | Functional activity of the novel Alzheimer's amyloid β peptide interacting domain (AID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. <i>Gene</i> , 2011 , 488, 13-22 | 3.8 | 58 |
| 160 | MicroRNA-101 downregulates Alzheimer's amyloid- β precursor protein levels in human cell cultures and is differentially expressed. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 404, 889-95 | 3.4 | 158 |
| 159 | Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. <i>Neurology</i> , 2011 , 76, 1344-52 | 6.5 | 98 |
| 158 | Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid- β precursor protein and amyloid- β peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteins in the prefrontal cortex of rats. <i>Neuroscience</i> , 2011 , 184, 139-50 | 3.9 | 27 |
| 157 | Increased secreted amyloid precursor protein- β (sAPP β) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. <i>PLoS ONE</i> , 2011 , 6, e20405 | 3.7 | 86 |
| 156 | Oxidative insults to neurons and synapse are prevented by aged garlic extract and S-allyl-L-cysteine treatment in the neuronal culture and APP-Tg mouse model. <i>Journal of Neurochemistry</i> , 2011 , 117, 388-402 | 6 | 74 |
| 155 | Targets for AD treatment: conflicting messages from β secretase inhibitors. <i>Journal of Neurochemistry</i> , 2011 , 117, 359-74 | 6 | 49 |
| 154 | Identification of blood biomarkers for psychosis using convergent functional genomics. <i>Molecular Psychiatry</i> , 2011 , 16, 37-58 | 15.1 | 127 |
| 153 | Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (A β) peptide and phospho-tau. <i>Journal of Psychiatric Research</i> , 2011 , 45, 539-47 | 5.2 | 34 |
| 152 | The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. <i>Journal of Neural Transmission</i> , 2011 , 118, 493-507 | 4.3 | 47 |
| 151 | An integrated approach to genome studies. <i>Science</i> , 2011 , 331, 147 | 33.3 | 10 |
| 150 | Current drug targets for modulating Alzheimer's amyloid precursor protein: role of specific micro-RNA species. <i>Current Medicinal Chemistry</i> , 2011 , 18, 3314-21 | 4.3 | 26 |
| 149 | The "aged garlic extract:" (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD). <i>Current Medicinal Chemistry</i> , 2011 , 18, 3306-13 | 4.3 | 68 |

148 The Genetics of Autism **2011**, 77-97

147 A polymeric nanoparticle formulation of curcumin (NanoCurc) ameliorates CCl₄-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. *Laboratory Investigation*, **2011**, 91, 1383-95 5.9 80

146 Rivastigmine lowers A β and increases sAPP β levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. *PLoS ONE*, **2011**, 6, e21954 3.7 45

145 A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. *Journal of Neurochemistry*, **2010**, 112, 843-53 6 39

144 GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 19, 1205-19 4.3 233

143 Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A β) peptide in the human neuroblastoma cells. *Neuroscience Letters*, **2010**, 470, 1-5 3.3 39

142 Co-localization of the amyloid precursor protein and Notch intracellular domains in nuclear transcription factories. *Neurobiology of Aging*, **2010**, 31, 58-73 5.6 51

141 Novel drug targets based on metallobiology of Alzheimer's disease. *Expert Opinion on Therapeutic Targets*, **2010**, 14, 1177-97 6.4 40

140 Beyond the signaling effect role of amyloid- β on the processing of APP, and its clinical implications. *Experimental Neurology*, **2010**, 225, 51-4 5.7 32

139 Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2010**, 153B, 185-201 3.5 28

138 The KATP channel activator diazoxide ameliorates amyloid- β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 22, 443-57 4.3 84

137 Melatonin alters age-related changes in transcription factors and kinase activation. *Neurochemical Research*, **2010**, 35, 2035-42 4.6 8

136 The "LEARN" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. *Experimental Gerontology*, **2010**, 45, 291-6 4.5 87

135 Coming to grips with complex disorders: genetic risk prediction in bipolar disorder using panels of genes identified through convergent functional genomics. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2010**, 153B, 850-77 3.5 41

134 Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. *Journal of Neuroscience Research*, **2010**, 88, 143-54 4.4 92

133 Role of Nitric Oxide in Neurodegeneration and Vulnerability of Neuronal Cells to Nitric Oxide Metabolites and Reactive Oxygen Species **2010**, 399-415

132 Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. *Journal of Alzheimer's Disease*, **2009**, 18, 211-30 4.3 27

131 Determination of high-affinity choline uptake (HACU) and choline acetyltransferase (ChAT) activity in the same population of cultured cells. *Brain Research*, **2009**, 1297, 160-8 3.7 12

| | | | |
|-----|---|------|-----|
| 130 | Epigenetics, oxidative stress, and Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2009 , 46, 1241-97.8 | | 266 |
| 129 | The LEARN model: an epigenetic explanation for idiopathic neurobiological diseases. <i>Molecular Psychiatry</i> , 2009 , 14, 992-1003 | 15.1 | 165 |
| 128 | Molecular and immunocytochemical characterization of primary neuronal cultures from adult rat brain: Differential expression of neuronal and glial protein markers. <i>Journal of Neuroscience Methods</i> , 2009 , 184, 294-302 | 3 | 22 |
| 127 | Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. <i>Current Opinion in Pharmacology</i> , 2009 , 9, 434-44 | 5.1 | 115 |
| 126 | Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2009 , 1790, 615-28 | 4 | 72 |
| 125 | Development and validation of the high-quality 'rapid method for swab' to genotype the HTTLPR serotonin transporter (SLC6A4) promoter polymorphism. <i>Psychiatric Genetics</i> , 2009 , 19, 72-82 | 2.9 | 6 |
| 124 | How Biochemical Pathways for Disease May be Triggered by Early-Life Events 2009 , 205-214 | | 1 |
| 123 | Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. <i>Neuron</i> , 2008 , 57, 680-90 | 13.9 | 162 |
| 122 | Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2008 , 36, 1282-7 ¹ | 5.1 | 100 |
| 121 | Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. <i>Journal of Neuroscience</i> , 2008 , 28, 3-9 | 6.6 | 373 |
| 120 | Co-localization and distribution of cerebral APP and SP1 and its relationship to amyloidogenesis. <i>Journal of Alzheimer's Disease</i> , 2008 , 13, 71-80 | 4.3 | 21 |
| 119 | 3rd IANA (International Academy on Nutrition and Aging) Meeting Nutrition, Exercise & Alzheimer and Clinical Trials on Sarcopenia August 12, 2008 Hyatt Regency Tamaya Resort 1300 Tuyuna Trail Santa Ana Pueblo, NM USA. <i>Journal of Nutrition, Health and Aging</i> , 2008 , 12, 419-426 | 5.2 | 1 |
| 118 | Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARN" model. <i>Biogerontology</i> , 2008 , 9, 375-9 | 4.5 | 49 |
| 117 | Dissociation Between the Potent β Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine 2008 , 445-462 | | 1 |
| 116 | Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2007 , 11, 481-9 | 4.3 | 8 |
| 115 | Apoptotic and behavioral sequelae of mild brain trauma in mice. <i>Journal of Neuroscience Research</i> , 2007 , 85, 805-15 | 4.4 | 80 |
| 114 | Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2007 , 103, 1237-57 | 6 | 34 |
| 113 | Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2007 , 9, 157-68 | 4.6 | 12 |

| | | | |
|-----|--|------|-----|
| 112 | The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 320, 386-96 | 4.7 | 103 |
| 111 | Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. <i>Current Medicinal Chemistry</i> , 2007 , 14, 2848-64 | 4.3 | 67 |
| 110 | How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. <i>Current Alzheimer Research</i> , 2007 , 4, 219-28 | 3 | 111 |
| 109 | Effects of melatonin and age on gene expression in mouse CNS using microarray analysis. <i>Neurochemistry International</i> , 2007 , 50, 336-44 | 4.4 | 33 |
| 108 | Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease 2007 , 9, 157 | | 1 |
| 107 | Aluminum and copper in drinking water enhance inflammatory or oxidative events specifically in the brain. <i>Journal of Neuroimmunology</i> , 2006 , 176, 16-23 | 3.5 | 91 |
| 106 | A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. <i>Current Alzheimer Research</i> , 2006 , 3, 81-90 | 3 | 54 |
| 105 | Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors. <i>Current Alzheimer Research</i> , 2006 , 3, 475-83 | 3 | 26 |
| 104 | Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 855-62 | 4.7 | 36 |
| 103 | Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. <i>FASEB Journal</i> , 2006 , 20, 788-90 | 0.9 | 139 |
| 102 | Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 2174-85 | 8.3 | 64 |
| 101 | Genes are not our destiny: the somatic epitype bridges between the genotype and the phenotype. <i>Nature Reviews Neuroscience</i> , 2006 , 7, 976-976 | 13.5 | 12 |
| 100 | High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. <i>Journal of Child Neurology</i> , 2006 , 21, 444-9 | 2.5 | 89 |
| 99 | Where the actions of environment (nutrition), gene and protein meet: beneficial role of fruit and vegetable juices in potentially delaying the onset of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006 , 10, 359-61; discussion 363-4 | 4.3 | 7 |
| 98 | Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2006 , 10, 9-16 | 4.3 | 10 |
| 97 | Neuronal differentiation is accompanied by increased levels of SNAP-25 protein in fetal rat primary cortical neurons: implications in neuronal plasticity and Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1086, 54-65 | 6.5 | 16 |
| 96 | BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation. <i>Journal of Molecular Neuroscience</i> , 2006 , 28, 193-210 | 3.3 | 12 |
| 95 | Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells. <i>Journal of Molecular Neuroscience</i> , 2006 , 29, 65-80 | 3.3 | 22 |

| | | | |
|----|---|------|-----|
| 94 | Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter. <i>Journal of Molecular Neuroscience</i> , 2006 , 29, 81-99 | 3.3 | 12 |
| 93 | Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 986-94 | 8.3 | 47 |
| 92 | NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. <i>Molecular Brain Research</i> , 2005 , 136, 177-88 | | 21 |
| 91 | Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2005 , 26, 1329-41 | 5.6 | 39 |
| 90 | Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1056, 430-49 | 6.5 | 32 |
| 89 | An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2005 , 2, 281-90 | 3 | 99 |
| 88 | Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 17213-8 | 11.5 | 519 |
| 87 | Characterization of the APP proximal promoter and 5'-untranslated regions: identification of cell type-specific domains and implications in APP gene expression and Alzheimer's disease. <i>FASEB Journal</i> , 2005 , 19, 653-5 | 0.9 | 33 |
| 86 | Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. <i>FASEB Journal</i> , 2005 , 19, 2083-4 | 0.9 | 75 |
| 85 | The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. <i>Journal of Neuroscience</i> , 2005 , 25, 823-9 | 6.6 | 288 |
| 84 | Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. <i>Journal of Biological Chemistry</i> , 2004 , 279, 20378-86 | 5.4 | 124 |
| 83 | Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. <i>FASEB Journal</i> , 2004 , 18, 1288-90 | 0.9 | 41 |
| 82 | Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. <i>FASEB Journal</i> , 2004 , 18, 1037-9 | 0.9 | 55 |
| 81 | Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region. <i>Journal of Neurochemistry</i> , 2004 , 90, 1432-44 | 6 | 25 |
| 80 | Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. <i>Journal of Pineal Research</i> , 2004 , 36, 224-31 | 10.4 | 88 |
| 79 | Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. <i>Journal of Molecular Neuroscience</i> , 2004 , 23, 225-33 | 3.3 | 54 |
| 78 | Functional characterization of amyloid beta precursor protein regulatory elements: rationale for the identification of genetic polymorphism. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1030, 282-8 | 6.5 | 20 |
| 77 | Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1030, 310-6 | 6.5 | 21 |

| | | | |
|----|--|------|-----|
| 76 | The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1035, 34-48 | 6.5 | 45 |
| 75 | Neuroprotection from complement-mediated inflammatory damage. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1035, 147-64 | 6.5 | 32 |
| 74 | Retardation of brain aging by chronic treatment with melatonin. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1035, 197-215 | 6.5 | 19 |
| 73 | Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1035, 216-30 | 6.5 | 15 |
| 72 | New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1035, 290-315 | 6.5 | 76 |
| 71 | Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin. <i>Journal of Pineal Research</i> , 2004 , 36, 165-70 | 10.4 | 40 |
| 70 | Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. <i>Journal of Neuroscience Research</i> , 2004 , 75, 565-72 | 4.4 | 130 |
| 69 | Gene structure and organization of the human beta-secretase (BACE) promoter. <i>FASEB Journal</i> , 2004 , 18, 1034-6 | 0.9 | 155 |
| 68 | Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 651-60 | 5.6 | 99 |
| 67 | Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 581-7 | 5.6 | 21 |
| 66 | Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. <i>Journal of Pineal Research</i> , 2004 , 36, 217-23 | 10.4 | 79 |
| 65 | Cholesterol and APOE genotype interact to influence Alzheimer disease progression. <i>Neurology</i> , 2004 , 62, 1869-71 | 6.5 | 86 |
| 64 | Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. <i>Current Pharmaceutical Design</i> , 2004 , 10, 3111-9 | 3.3 | 74 |
| 63 | Metal and inflammatory targets for Alzheimer's disease. <i>Current Drug Targets</i> , 2004 , 5, 535-51 | 3 | 133 |
| 62 | Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. <i>Current Drug Targets</i> , 2004 , 5, 517-28 | 3 | 53 |
| 61 | A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. <i>Current Drug Targets</i> , 2003 , 4, 97-112 | 3 | 170 |
| 60 | Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2003 , 5, 81-90 | 4.3 | 71 |
| 59 | Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease?: effects of beta-amyloid deposition on NOS in transgenic mouse brain with AD pathology. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1010, 639-42 | 6.5 | 15 |

| | | | |
|----|---|------|-----|
| 58 | A proximal gene promoter region for the beta-amyloid precursor protein provides a link between development, apoptosis, and Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1010, 643-7 | 6.5 | 15 |
| 57 | Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. <i>Journal of Neuroscience Research</i> , 2003 , 72, 603-12 | 4.4 | 269 |
| 56 | APH1, PEN2, and Nicastrin increase Abeta levels and gamma-secretase activity. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 305, 502-9 | 3.4 | 41 |
| 55 | Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. <i>Evidence-Based Mental Health</i> , 2003 , 6, 94 | 11.1 | 2 |
| 54 | Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. <i>Journal of Biological Chemistry</i> , 2003 , 278, 18408-18 | 5.4 | 100 |
| 53 | Developmental expression of the beta-amyloid precursor protein and heat-shock protein 70 in the cerebral hemisphere region of the rat brain. <i>Annals of the New York Academy of Sciences</i> , 2002 , 965, 324-33 | 6.5 | 15 |
| 52 | Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. <i>Annals of the New York Academy of Sciences</i> , 2002 , 965, 364-72 | 6.5 | 36 |
| 51 | Targeting APP metabolism for the treatment of Alzheimer's disease. <i>Drug Development Research</i> , 2002 , 56, 211-227 | 5.1 | 13 |
| 50 | Current drug targets for Alzheimer's disease treatment. <i>Drug Development Research</i> , 2002 , 56, 267-281 | 5.1 | 146 |
| 49 | Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. <i>Journal of Molecular Neuroscience</i> , 2002 , 19, 77-82 | 3.3 | 53 |
| 48 | The role of the carboxyl-terminal fragments of amyloid precursor protein in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2002 , 973, 334-9 | 6.5 | 13 |
| 47 | Functional characterization of the 5'-regulatory region of the murine apolipoprotein gene. <i>Annals of the New York Academy of Sciences</i> , 2002 , 973, 340-4 | 6.5 | 10 |
| 46 | Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2002 , 973, 463-7 | 6.5 | 69 |
| 45 | Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2002 , 1, 1-31 | 4.6 | 147 |
| 44 | An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. <i>Journal of Biological Chemistry</i> , 2002 , 277, 45518-28 | 5.4 | 395 |
| 43 | A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 300, 958-66 | 4.7 | 234 |
| 42 | Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 5090-7 | 8.3 | 95 |
| 41 | Dietary modulation of age-related changes in cerebral pro-oxidant status. <i>Neurochemistry International</i> , 2002 , 40, 123-30 | 4.4 | 31 |

| | | | |
|----|--|------|-----|
| 40 | Melatonin, Nitric Oxide Synthase and Oxidative Stress: Implications in Aging. <i>Advances in Behavioral Biology</i> , 2002 , 245-248 | | |
| 39 | Phenserine Regulates Translation of Amyloid Precursor Protein Message. <i>Advances in Behavioral Biology</i> , 2002 , 211-215 | | |
| 38 | Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 7605-10 | 11.5 | 178 |
| 37 | Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2000 , 176, 60-7 | 3.8 | 53 |
| 36 | The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. <i>Acta Neurologica Scandinavica</i> , 2000 , 176, 74-84 | 3.8 | 55 |
| 35 | Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 387-93 | 6.5 | 19 |
| 34 | Efficient DNA transfection in neuronal and astrocytic cell lines. <i>Molecular Biology Reports</i> , 2000 , 27, 113-2.8 | | 19 |
| 33 | Analysis of the 5'-flanking region of the beta-amyloid precursor protein gene that contributes to increased promoter activity in differentiated neuronal cells. <i>Molecular Brain Research</i> , 2000 , 77, 185-98 | | 17 |
| 32 | Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue. <i>Brain Research Protocols</i> , 2000 , 5, 257-65 | | 71 |
| 31 | Melatonin suppression by light in euthymic bipolar and unipolar patients. <i>Archives of General Psychiatry</i> , 2000 , 57, 572-9 | | 174 |
| 30 | Interactions between melatonin, reactive oxygen species, and nitric oxide. <i>Annals of the New York Academy of Sciences</i> , 1999 , 893, 325-30 | 6.5 | 27 |
| 29 | Effect of oxidative stress on DNA damage and beta-amyloid precursor proteins in lymphoblastoid cell lines from a Nigerian population. <i>Annals of the New York Academy of Sciences</i> , 1999 , 893, 331-6 | 6.5 | 15 |
| 28 | Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. <i>Journal of Pineal Research</i> , 1999 , 26, 137-46 | 10.4 | 69 |
| 27 | Increased vulnerability of neuronal cell lines to sodium nitroprusside-mediated toxicity is caused by the decreased level of nitric oxide metabolites. <i>Journal of Molecular Neuroscience</i> , 1999 , 13, 77-92 | 3.3 | 18 |
| 26 | Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 1999 , 269, 67-70 | 3.3 | 39 |
| 25 | Promoter activity of the beta-amyloid precursor protein gene is negatively modulated by an upstream regulatory element. <i>Molecular Brain Research</i> , 1999 , 71, 32-41 | | 18 |
| 24 | Molecular cloning of the promoter of the gene encoding the Rhesus monkey beta-amyloid precursor protein: structural characterization and a comparative study with other species. <i>Gene</i> , 1998 , 217, 151-64 | 3.8 | 34 |
| 23 | Functional identification of the promoter of the gene encoding the Rhesus monkey beta-amyloid precursor protein. <i>Gene</i> , 1998 , 217, 165-76 | 3.8 | 42 |

| | | | |
|----|--|------|-----|
| 22 | An region upstream of the gene promoter for the beta-amyloid precursor protein interacts with proteins from nuclear extracts of the human brain and PC12 cells. <i>Molecular Brain Research</i> , 1998 , 58, 112-22 | | 23 |
| 21 | The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. <i>Molecular Brain Research</i> , 1998 , 62, 131-40 | | 72 |
| 20 | Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain. <i>Life Sciences</i> , 1998 , 63, 2121-31 | 6.8 | 8 |
| 19 | Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. <i>Neurology</i> , 1998 , 50, 669-77 | 6.5 | 180 |
| 18 | The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. <i>Life Sciences</i> , 1997 , 61, 1985-92 | 6.8 | 9 |
| 17 | Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. <i>Annals of the New York Academy of Sciences</i> , 1997 , 826, 416-21 | 6.5 | 44 |
| 16 | Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. <i>Journal of Molecular Neuroscience</i> , 1997 , 9, 75-92 | 3.3 | 72 |
| 15 | Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. <i>Journal of Molecular Neuroscience</i> , 1996 , 7, 41-9 | 3.3 | 43 |
| 14 | Efficient transfection of DNA by mixing cells in suspension with calcium phosphate. <i>Nucleic Acids Research</i> , 1995 , 23, 3609-11 | 20.1 | 24 |
| 13 | Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. <i>Molecular Brain Research</i> , 1995 , 32, 233-40 | | 89 |
| 12 | Molecular analysis of the promoter region of the gene encoding the beta-amyloid precursor protein. <i>Indian Journal of Biochemistry and Biophysics</i> , 1995 , 32, 329-35 | | 2 |
| 11 | Effect of ionophores on the processing of the beta-amyloid precursor protein in different cell lines. <i>Cellular and Molecular Neurobiology</i> , 1994 , 14, 297-313 | 4.6 | 15 |
| 10 | Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. <i>Journal of Neuroscience Research</i> , 1994 , 37, 777-87 | 4.4 | 108 |
| 9 | Melatonin-like immunoreactivity in the presence of different chemicals as determined by the radioimmunoassay. <i>Biochemical Medicine and Metabolic Biology</i> , 1994 , 51, 51-4 | | 6 |
| 8 | Factors that influence radioimmunoassay of human plasma melatonin: a modified column procedure to eliminate interference. <i>Biochemical Medicine and Metabolic Biology</i> , 1993 , 49, 36-50 | | 14 |
| 7 | The stability of beta-amyloid precursor protein in nine different cell types. <i>IUBMB Life</i> , 1993 , 29, 849-58 | | 3 |
| 6 | DNA isolation by a rapid method from human blood samples: effects of MgCl ₂ , EDTA, storage time, and temperature on DNA yield and quality. <i>Biochemical Genetics</i> , 1993 , 31, 321-8 | 2.4 | 79 |
| 5 | The cholinergic agonist carbachol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells. <i>Biochemistry International</i> , 1992 , 28, 853-60 | | 12 |

- 4 A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. *Nucleic Acids Research*, **1991**, 19, 5444 20.1 1645
- 3 The promoter activity of the gene encoding Alzheimer beta-amyloid precursor protein (APP) is regulated by two blocks of upstream sequences. *Molecular Brain Research*, **1991**, 9, 253-7 87
- 2 Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene. *Biochemical and Biophysical Research Communications*, **1989**, 159, 297-304 3.4 65
- 1 Studies with the Memory-Enhancing Drug AIT-082 in PC12 Cells 759-767